Arterial Research Initiative

The POPPY STUDY (Preconception to post-partum cardiovascular function in primigravid pregnancy) Novel use of pressure pulse waveform analysis technologies to identify early risk factors for preeclampsia and other placental syndromes.


How will the SphygmoCor® technology enable, enhance, or accelerate your research?

The POPPY study is the first, adequately powered, study of its kind to provide a comprehensive picture of haemodynamic adaptations to pregnancy, by monitoring women before conception, during pregnancy and again post-partum. Integration of SphygmoCor technology at all timepoints within the POPPY study will provide extremely novel data, allowing us to examine any associations between vascular measures and occurrence of placental syndromes including preeclampsia, gestational hypertension, and fetal growth restriction. Utilising central pressure and pulse wave analysis parameters will enable the characterisation of distinct phenotypes at risk of placental syndromes and better understand long term cardiovascular impacts on women’s health. Utilising accessible technology such as the PULSE device will also expand data collection beyond in-clinic visits to at home or remote monitoring. The POPPY study has a Ugandan arm, which will enable assessment of the feasibility of integrating SphygmoCor technology in low resource settings – a potential game-changer. Additionally, Sub-Saharan populations are at greater risk of placental syndromes with worse pregnancy outcomes, therefore investigating this demographic will provide invaluable insights. For example, incorporating the ConneQt data cloud, we can demonstrate the capabilities of remote monitoring and its potential for providing easier access to specialists in remote or disadvantaged communities. Feasibility assessments can inform future health policies helping democratise access to healthcare services, particularly for marginalized communities, reducing health disparities and advancing global health equality. The POPPY study will identify at risk vascular phenotypes with SyphgmoCor technology, which will integrate vascular measures in practise to ensure early detection of at-risk women for targeted treatment facilitating proactive prevention of placental syndromes.